IPI-549 Inhibitor

IPI-549 is an inhibitor of PI3Kgamma (IC50 = 16, 3,200, 3,500, and >8,400nM for PI3Kgamma, PI3Kalpha, PI3Kbeta, and PI3Kdelta, respectively)

1. De Vera AA1, Gupta P.et al.Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.Cancer Lett. 2019 Feb 1;442:91-103
2. Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-gamma Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7 (9):862-7.
3. De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016 Nov 17;539 (7629):443-447.

Small volumes of IPI-549, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5751841 is an inhibitor targeting IPI-549.